Diaceutics PLC

PDMR Shareholding/Share Incentive Plan

Belfast and London, 2 October 2024 Diaceutics PLC (AIM: DXRX)a leading technology and solutions provider to the pharma and biotech industry, has been notified that on 30 September 2024, Global Shares Trustees (UK) Limited (the "UK Trust") and Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trus; have purchased ordinary shares of £0.002 in the capital of the Company ("Shares") on behalf of Susanne Munksted, Jordan Clark, Nick Roberts and Jillian Beggs (PDMRs), in respect of their purchase of Shares pursuant to the Company's UK and Global Share Incentive Plan ("the SIP Schemes") for employeesThese purchases will be made each month until further notice.

In accordance with the SIP Schemes, the Company has matched these purchases with a matched share award over an equivalent number of Shares purchased by the employee, in the proportion of 1:1.

Enquiries:

Diaceutics PLC Nick Roberts, Chief Financial Officer

Canaccord Genuity Limited (Nomad & Broker) Simon Bridges, Andrew Potts, Harry Rees

Alma Strategic Communications Caroline Forde, Kinvara Verdon Tel: +44 (0)28 9040 6500 investorrelations@diaceutics.com

Tel: +44 (0)20 7253 8000

Tel: +44(0)20 3405 0205 diaceutics@almastrategic.com

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network [®].

Noti	fication of a Transaction pur	suant to Article 19(1) of Regulation (EU) No. 596/2014		
1	Details of the person discharging managerial responsibilities/person closely associated			
a.	Name	Susanne Munksted		
2	Reason for notification			
a.	Position/Status	Chief Precision Medicine Officer		
b.	Initial notification/ Amendment	Initial		
3	Details of the issuer, em monitor	ission allowance market participant, auction platform, auctioneer or auction		
a.	Name	Diaceutics PLC		
b.	LEI	213800VEWQBB39ZB8J81		
4		n(s): section to be repeated for (i) each type of instrument; (ii) each type of te; and (iv) each place where transactions have been conducted		
a.	Description of the financial instrument, type of instrument	Ordinary shares of £0.002 each		
	Identification Code	ISIN: GB00BJOTGV64		

b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Global Share Incentive Plan ("SIP")			
с.	Price(s) and volume(s)	Share purchase:			
		Price(s)	Volume(s)		
		134 p	108		
		Conditional sha	re award:		
		Price(s)	Volume(s)		
		Nil	108		
e.	Date of the transaction	Share purchase and C	onditional share award: 30	September	2024
f.	Place of the transaction	Share Purchase: AIM N	Market of the London Stock I	Exchange	
		Conditional share awa	ard: Off-Market		

1	Details of the person dis	Details of the person discharging managerial responsibilities/person closely associated				
a.	Name	Jordan Clark				
2	Reason for notification					
a.	Position/Status	Chief Data Officer				
o.	Initial notification/ Amendment	Initial				
3	Details of the issuer, em monitor	l ission allowance market participant, auction platform, auctioneer or auction				
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
		(s): section to be repeated for (i) each type of instrument; (ii) each type of e; and (iv) each place where transactions have been conducted Ordinary shares of £0.002 each				
•	transaction; (iii) each da	e; and (iv) each place where transactions have been conducted				
4 a.	transaction; (iii) each da Description of the financial instrument, type of instrument	e; and (iv) each place where transactions have been conducted Ordinary shares of £0.002 each ISIN: GB00BJQTGV64 Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share				
a.	transaction; (iii) each dar Description of the financial instrument, type of instrument Identification Code Nature of the	e; and (iv) each place where transactions have been conducted Ordinary shares of £0.002 each				
а. b.	transaction; (iii) each dat Description of the financial instrument, type of instrument Identification Code Nature of the transaction	e; and (iv) each place where transactions have been conducted Ordinary shares of £0.002 each ISIN: GB00BJQTGV64 Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP")				
а. b.	transaction; (iii) each dat Description of the financial instrument, type of instrument Identification Code Nature of the transaction	e; and (iv) each place where transactions have been conducted Ordinary shares of £0.002 each ISIN: GB00BJQTGV64 Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP") Share purchase:				
).	transaction; (iii) each dat Description of the financial instrument, type of instrument Identification Code Nature of the transaction	e; and (iv) each place where transactions have been conducted Ordinary shares of £0.002 each ISIN: GB00BJQTGV64 Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP") Share purchase: Price(s) Volume(s)				
э. Э.	transaction; (iii) each dat Description of the financial instrument, type of instrument Identification Code Nature of the transaction	e; and (iv) each place where transactions have been conducted Ordinary shares of £0.002 each ISIN: GB00BJQTGV64 Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP") Share purchase: Price(s) Volume(s) 134 p 112				

e.	Date of the transaction	Share purchase and Matched Share award: 30 September 2024
f.	Place of the transaction	Share Purchase: AIM Market of the London Stock Exchange Matched Share Award: Off-Market

Notif	ication of a Transaction purs	uant to Article 19(1) of	Regulation (EU) No. 596/2	2014
1	Details of the person disc	harging managerial resp	onsibilities/person closel	y associated
a.	Name	Nick Roberts		
2	Reason for notification			
a.	Position/Status	Chief Finance Officer		
b.	Initial notification/ Amendment	Initial		
3	Details of the issuer, emis monitor	ssion allowance market	participant, auction platfo	orm, auctioneer or auction
a.	Name	Diaceutics PLC		
b.	LEI	213800VEWQBB39ZE	38J81	
4	Details of the transaction transaction; (iii) each date			trument; (ii) each type of en conducted
a.	Description of the financial instrument, type of instrument	Ordinary shares of £	0.002 each	
	Identification Code	ISIN: GB00BJQTGV64		
b.	Nature of the transaction		ard over Shares under th	s matched by the grant of e Diaceutics plc UK Share
c.	Price(s) and volume(s)	Share purchase	2:	
		Price(s)	Volume(s)	
		134 p	112	
		Matched share	e award:	
		Price(s)	Volume(s)	
		Nil	112	
e.	Date of the transaction	Share purchase and I	Natched Share award: 30	September 2024
<u>r</u>		Change Durch and Alla	Manhat af the London Of	al. Evaluation
f.	Place of the transaction	Share Purchase: AIM Matched Share Awar	Market of the London Sto d: Off-Market	ck Exchange
		1		

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

tification	Diaceutics PLC 213800VEWQBB39ZI : section to be repeat	participant, auction platform 38J81 ted for (i) each type of instru iere transactions have been o	nent; (ii) each type of	
ation/ issuer, emissic transaction(s): ii) each date; a f the rument,	Initial on allowance market Diaceutics PLC 213800VEWQBB39ZI : section to be repeat and (iv) each place wh	participant, auction platform 38J81 ted for (i) each type of instru iere transactions have been o	nent; (ii) each type of	
ation/ issuer, emissio transaction(s): ii) each date; a f the rument,	Initial on allowance market Diaceutics PLC 213800VEWQBB39ZI : section to be repeat and (iv) each place wh	participant, auction platform 38J81 ted for (i) each type of instru iere transactions have been o	nent; (ii) each type of	
issuer, emissic transaction(s): ii) each date; a f the rument,	on allowance market Diaceutics PLC 213800VEWQBB39Zi : section to be repeat and (iv) each place wh	38J81 ted for (i) each type of instru lere transactions have been o	nent; (ii) each type of	
transaction(s): ii) each date; a f the rument,	Diaceutics PLC 213800VEWQBB39ZI : section to be repeat and (iv) each place wh	38J81 ted for (i) each type of instru lere transactions have been o	nent; (ii) each type of	
transaction(s): ii) each date; a f the rument,	213800VEWQBB392f I: section to be repeat and (iv) each place wh	ted for (i) each type of instru lere transactions have been o		
transaction(s): ii) each date; a f the rument,	: section to be repea and (iv) each place wh	ted for (i) each type of instru lere transactions have been o		
ii) each date; a f the rument,	and (iv) each place wh	ere transactions have been o		
rument,	Ordinary shares of £	0.002 each		
Code	ISIN: GB00BJQTGV64	l.		
		ionary purchase of Shares m vard over Shares under the D)		
olume(s)	Share purchas	2:		
	Price(s)	Volume(s)		
	134 p	112		
	Matched share award:			
	Price(s)	Volume(s)		
	Nil	112		
insaction	Share purchase and	Matched Share award: 30 Sep	otember 2024	
			Exchange	
1	nsaction	nsaction Share purchase and ansaction Share Purchase: AIM	nsaction Share purchase and Matched Share award: 30 Sep	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END

DSHQKDBKKBDBOKK